Intrathecal Pain Therapy for Cancer: Practical Recommendations From MASCC

Intrathecal Pain Therapy for Cancer: Practical Recommendations From MASCC

By Ivan Urits, MD – Board Certified in Anesthesiology and Pain Medicine

Published September 30, 2025 | Category: Pain Medicine

When cancer pain cannot be controlled with standard medications, or side effects become intolerable, delivering medication directly to the spinal fluid through an implanted pump can help. This intrathecal approach uses tiny doses, but errors in dosing or drug choice can be dangerous. The Multinational Association of Supportive Care in Cancer (MASCC) published practice recommendations in 2025 in Supportive Care in Cancer.

This summary is based on the published abstract. Read the abstract on PubMed

What the authors did

A group of experts selected by MASCC developed clinical practice advice on spinal (intrathecal) drug delivery for cancer-related pain, recognizing that some aspects cannot be fully addressed by evidence alone.

Key recommendations

  • Refractory cancer pain means inadequate relief or uncontrolled side effects despite comprehensive pain management.
  • Intrathecal delivery allows very small doses with major effects while avoiding many systemic side effects.
  • Morphine and hydromorphone are the opioids of choice; adding local anesthetics can help when the catheter tip is placed near the painful segment.
  • Ziconotide requires slow dose titration.
  • When converting from oral morphine, a 100:1 oral-to-intrathecal ratio is suggested for patients on high systemic doses, and a more conservative 300:1 ratio for patients switching mainly because of side effects and taking lower doses.
  • Intrathecal boluses alone may not adequately treat sudden breakthrough pain.
  • Decisions should be shared, considering indications, prior treatments, prognosis, timing, benefits and complications.

Why this matters

Dose conversion is one of the highest-risk steps in starting intrathecal therapy, because errors can cause overdose or withdrawal. Clear conversion guidance and a shared decision-making approach help protect very vulnerable patients.

Limitations

These are expert recommendations, partly based on clinical experience rather than high-quality trials. Local practice and device differences may require adjustments.

Safety takeaways: how to apply it

For pain physicians and procedure teams

  • Use conservative dose conversions, and monitor closely after starting or changing intrathecal therapy.
  • Titrate ziconotide slowly, and watch for side effects.
  • Plan for breakthrough pain rather than relying on intrathecal boluses alone.

For hospitals, clinics and safety leaders

  • Use standardized protocols and double checks for intrathecal drug preparation and pump programming.

For patients and families

  • Ask how the dose was calculated, what side effects to watch for and whom to call at any hour.

Reference

  1. Mercadante S, Candido K, Staats P, Davis M. Spinal analgesia in cancer pain management-MASCC general practice recommendations. Support Care Cancer. 2025 Jul 09;33(8):674. doi:10.1007/s00520-025-09685-2. PMID: 40634640. PubMed: https://pubmed.ncbi.nlm.nih.gov/40634640/

This article is educational information, not legal or medical advice.

Previous
Previous

Major Complications After Cervical Transforaminal Steroid Injections Were Rare in a Large Database

Next
Next

Epidural Steroid Injections Linked to Higher Fracture Risk in Older Adults